Is your bladder feeling the signs of age? Spending too much time in the bathroom? Allergan's
Of course, the wrinkle treatment isn't making patients' bladders look more youthful. Instead, the neurotoxin is reducing muscle activity, the same way it does with wrinkles and migraines, which it's currently approved to treat.
In a pair of phase 3 trials, the number of daily incontinence episodes was greatly reduced in patients who received a Botox injection compared with those who got a placebo. Allergan didn't release the full data, but based on the p-value of less than 0.001, it's pretty clear the drug works.
The results aren't all that surprising; Botox is already approved as a treatment for overactive bladder associated with a neurological condition like a spinal cord injury or multiple sclerosis or for patients who can't tolerate other drugs used to treat the condition.
Allergan expects to present the full data at an upcoming medical meeting and has already applied for expanded use in the United States and European Union.
An injection into the bladder muscle with a neurotoxin, however effective, probably isn't going to be the first choice for patients and their doctors, though. In fact, Allergan isn't even targeting those first-line patients, choosing instead to go after patients who have failed other treatments such as Pfizer's
The treatment of overactive bladder may never reach the level of the cosmetics sales of Botox, but any incremental addition is still a welcome addition. And patients can get overactive bladders that they want to treat in good times and bad, unlike winkles that can be a little more sensitive to the economic cycles.
Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Pfizer and Johnson & Johnson and creating a diagonal call position in Johnson & Johnson. The Motley Fool has a disclosure policy. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
We Believe Healthcare's Next Biotech Buyout Target Is…
Which biotech company will be the next buyout target? To answer this question, we turned to three of our healthcare contributors, and this is what they had to say.
Can This Pharma Go From Good to Great?
Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?
Bill Ackman Made His Investors $4.5 Billion Last Year -- Here's How
Bill Ackman's 2014 performance proves that a pricey market still contains undervalued stocks.